Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures.

A Hoering,J D Shaughnessy,F Van Rhee,Y Alsayed,S Waheed,B P Nair,B Barlogie,J Crowley,J Haessler,R Sexton

doi:10.1200/jco.2010.28.15_suppl.8120

Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures.

A Hoering, J D Shaughnessy + Show 8 more

https://doi.org/10.1200/jco.2010.28.15_suppl.8120

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2010

#Total Therapy 2 #Multiple Myeloma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

8120 Background: Little is known about the genomic progression in MM. GEP provides the most comprehensive insight into global gene expression. With access to BL and REL MM samples in TT2 and TT3, w...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.